bioRxiv Science⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.1101/2023.12.28.573519

Fractal Dimension and Lacunarity Measures of Glioma Subcomponents Provide a Quantitative Platform Discriminative of IDH Status: A Radiogenomics Approach in Gliomas

Yadav, N.·Mohanty, A.·Aswin, V.·Mishrra, N.·Tiwari, V.
View original source ↗Export metadata ↓

Abstract

BackgroundThe presence of structural and geometric variations within gliomas, even among those with similar histologic grades, reflects the phenotypic heterogeneity unique to a genetic and epigenetic landscape. Whole glioma mass comprises of various subcomponents identified on MR imaging: enhancing, nonenhancing, necrosis, and edema fractions in varied fractions across patients. The geometry of whole tumor mass and the glioma subcomponents is highly irregular. Thereby, traditional Euclidean geometry is not suitable for quantifying the geometric dimensions. Here, we employ non-Euclidean geometric measurements: Fractal Dimension and lacunarity of the glioma subcomponents as a discriminator of IDH and MGMT status of gliomas. MethodsFractality and Lacunarity measurements were obtained using the tumor masks generated for enhancing, nonenhancing, and edema subcomponents from the preoperative T1, T1c, and T2-Flair MRI. Fractality and lacunarity measures of each subcomponent were evaluated between IDH mutant and wildtype gliomas. The fractality and lacunarity measures in IDH mutant and wildtype gliomas were further stratified for MGMT methylated and unmethylated gliomas. The fractality and lacunarities were trained and tested using supervised ML modeling as discriminators of IDH and MGMT status. Further, Cox Hazard estimations and the Kaplan-Meir investigations were performed to evaluate the impact of fractality and lacunarity measures of glioma subcomponents on the overall survival of the patients. ResultsIDH wildtype gliomas had [~]2-fold higher fractality for the enhancing subcomponent compared to IDH mutant enhancing subcomponent, while IDH mutant gliomas showed higher fractality for the nonenhancing subcomponent. Furthermore, the edema subcomponent did not differ for fractality or lacunarity measures between IDH mutant and wildtype gliomas. Fractal or lacunarity measures for either of the three subcomponents do not vary across MGMT methylated and unmethylated status with a given IDH mutant or wildtype gliomas. A combination of fractal measures of the enhancing and nonenhancing subcomponents together provided highly accurate and sensitive discrimination of IDH status using the supervised ML models. Moreover, fractality measure [≥] 0.69 for the enhancing subcomponent was associated with shortened patient survival: a fractal dimension value corresponding to that of IDH wild type gliomas. However, fractality and lacunarity estimates were not sensitive for discrimination of MGMT status. ConclusionGlioma structural heterogeneity measured as fractality and lacunarity using routine structural MRI measurements provide a noninvasive quantitative platform definitive of the molecular subtype of gliomas: IDH mutant vs. wildtype. Establishing fractality and/or lacunarity quantities as signatures of prognostic molecular events provides an avenue to bypass the need of biopsy/surgical interventions for decision-making, determining the molecular subtypes and overall clinical management of gliomas. Importance of the StudyThe non-Euclidean geometric measurements such as fractal dimension and lacunarity of enhancing, nonenhancing, and edema subcomponents are potentially unique quantitative metrics, discriminative of IDH status and patient survival. Fractality and Lacunarity estimates using the conventional structural MRI (T1w, T1C, T2, and T2F) provide an easy-to-use quantitative radiogenomics platform for improved clinical decisions, bypassing the need for immediate surgical interventions to ascertain prognostic molecular markers in gliomas, which is likely to improve overall clinical management and outcomes. Key PointsO_LIIncreased fractal dimensions of the enhancing subcomponents in IDH wildtype tumors, suggestive of highly irregular geometry, may potentially serve as a quantitative noninvasive determinant of IDH wildtype tumors. C_LIO_LIA combined fractal estimation of enhancing and nonenhancing subcomponents is the optimal and accurate discriminator of IDH mutant vs. wildtype. C_LIO_LIHigh fractal dimension of enhancing subcomponent and reduced fractality of nonenhancing subcomponent is predictive of shortened patient survival. C_LI

Explore related subjects

cancer biologyPreprint

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Yadav, N., Mohanty, A., Aswin, V., Mishrra, N., Tiwari, V.. 2023-12-29. Fractal Dimension and Lacunarity Measures of Glioma Subcomponents Provide a Quantitative Platform Discriminative of IDH Status: A Radiogenomics Approach in Gliomas. https://doi.org/10.1101/2023.12.28.573519

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Ex vivo human tumor slices more accurately predict patient responses to an oncolytic virus than in vivo mouse models

Immunotherapies, including oncolytic viruses (OV), are promising therapies that can enhance anti-tumor immune responses. However, preclinical success of immunotherapies in mouse models has not always translated to clinical benefit in cancer patients. This study compared preclinical efficacy and mechanism of action for ASP9801, a vaccinia virus expressing IL-7 and IL-12, using mouse models of colorectal cancer (CRC) in vivo and in human organotypic tumor slice models ex vivo. The murine surrogate for ASP9801 significantly reduced tumor volumes in treated and abscopal tumors in two different CRC models in vivo (MC38 and RO100). Treatment efficacy was accentuated when combined with anti-PD1 treatment, and single-cell RNA sequencing analysis revealed depletion of tumor cells and increased T cell infiltration and activation in both treated and abscopal tumors. However, human tissue analysis ex vivo (E-slices) using PDX models and patient samples showed that ASP9801 is not effective in CRC, consistent with clinical trial results. On the other hand, ASP9801 was highly effective in GBM, indicating indication-specific efficacy of ASP9801, and how E-slice assays can be used to identify treatment-sensitive indications. This study demonstrates the superiority of E-slices over mouse models for predicting clinical response and its utility in planning clinical trials.

cancer biology↗
bioRxiv2026

Immune-cell depleted diffuse large B-cell lymphomas have reduced expression of MHC class I

Immunotherapy has transformed treatment for many cancers. In the aggressive and genetically heterogeneous diffuse large B-cell lymphoma (DLBCL), CD19 CAR T-cell therapy is highly effective, whereas immune checkpoint blockade has shown limited benefit. Loss of MHC expression is a common mechanism to escape T-cell cytotoxicity, and loss of MHC class I (MHC-I) and II are frequent in DLBCL. We applied imaging mass cytometry to diagnostic biopsies from younger, high-risk DLBCL patients to map the tumor microenvironment (TME) spatial architecture in relation to tumor cell MHC expression, mutational status, transcriptomic and proteomic profiles. Neighborhood analyses identified four TME subtypes: immune-cell depleted and three immune-infiltrated types (mixed, CD4 T cell-rich, CD8 T-cell/macrophage-rich). Depleted cases had shorter overall survival (p = 0.033) and increased expression of proteins involved in DNA replication and proliferation markers compared to infiltrated cases. Tumor cell MHC-I expression was heterogeneous. Cases with low frequency of MHC-I-pos tumor cells were enriched for the depleted TME type. MHC-I-pos tumor cells were surrounded by CD4 and CD8 T cells and M1 macrophages, whereas MHC-I-neg tumor cells were closer to other MHC-I-neg tumor cells. These findings suggest that TME-based classification incorporating tumor cell MHC-I status may improve individualized immunotherapy selection.

cancer biology↗
bioRxiv2026

Cross-species analysis links cell-cell communication rewiring to NOTCH2 during serous endometrial carcinogenesis

Cell-cell interactions shape the fate of mutant cells during cancer initiation but how these interactions evolve during progression to pathologically recognizable lesions remain poorly understood. Here, we investigated cell-cell communication during serous endometrial carcinoma (SEC; also known as uterine serous carcinoma) development using a lineage-traceable mouse model and cross-species analyses of the mouse and human neoplastic endometrium. In mice, the early, pre-dysplastic stage was marked by a global decrease in inferred cell-cell interactions, followed by extensive communication network rewiring during neoplastic progression. Pathway-specific analysis revealed a similar pattern for NOTCH signaling, with NOTCH2 emerging as the dominant NOTCH receptor in Trp53/Rb1-mutant immature epithelial cells. Functionally, NOTCH2 promoted the outgrowth of more proliferative mutant organoids. Cross-species transcriptomic analysis identified conserved immature epithelial states in mouse and human neoplastic endometrial epithelium. In human tissues, NOTCH2 was overexpressed in serous endometrial intraepithelial carcinoma, a precursor of SEC, and in overt SEC. Furthermore, elevated NOTCH2 expression was associated with poor patient survival. These findings link cell-cell communication rewiring during experimental SEC development to conserved neoplastic epithelial states and identify NOTCH2 as an early marker and a potential target of disease interception.

cancer biology↗